INS 2026 demonstrate how its innovative and unique neuromodulator portfolio consistently meets the needs of patients and practitioners, setting the company apart as a leader in this field.

Today, Galderma is well positioned to be the leader in all aspects of Injectable Aesthetics, having the in-house capabilities to discover, research, develop, manufacture, and market best-in-class products.

More details on Galderma’s scientific presentations at TOXINS 2026 can be foundhere.

About Relfydess (RelabotulinumtoxinA)
Pioneered by Galderma, Relfydess is the first and only ready-to-use liquid neuromodulator designed with PEARL Technology that is designed to preserve molecule integrity.1PEARL Technology is designed to deliver a highly active, innovative, complex-free molecule, with up to 39% of patients seeing effects from day one and up to 75% of patients maintaining improvements for six months.1,7,8Relfydess is optimized for simple volumetric dosing,
=*=*=*=*=*=
当前为第5/10页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页